IP Library Granted Patent US 7,795,413
Granted Patent B2
US 7,795,413 · App. 11/767,326 · Granted Sep 14, 2010

Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,795,413
App. No.
11/767,326
Granted
Sep 14, 2010
Kind
B2
Abstract

This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.

Claims (30)

1. An isolated nucleic acid molecule comprising

(a) SEQ ID NO: 9;

(b) SEQ ID NO: 11;

(c) SEQ ID NO: 21, SEQ ID NO: 17, and SEQ ID NO: 13; or

(d) SEQ ID NO: 23, SEQ ID NO: 19, and SEQ ID NO: 15.

2. An isolated host cell comprising the nucleic acid of claim 1 .

3. An isolated cell line comprising the nucleic acid of claim 1 .

4. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes

(a) SEQ ID NO: 10;

(b) SEQ ID NO: 12;

(c) SEQ ID NO: 22, SEQ ID NO: 18, and SEQ ID NO: 14;

(d) SEQ ID NO: 24, SEQ ID NO: 20, and SEQ ID NO: 16;

(e) SEQ ID NO: 40;

(f) SEQ ID NO: 41;

(g) SEQ ID NO: 42;

(h) SEQ ID NO: 43; or

(i) SEQ ID NO: 44.

5. An isolated host cell comprising the nucleic acid of claim 4 .

6. An isolated cell line comprising the nucleic acid of claim 4 .

7. An isolated nucleic acid or nucleic acids that encode(s) a nerve growth factor (NGF) antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment comprises

(a) SEQ ID NO: 10;

(b) SEQ ID NO: 12;

(c) SEQ ID NO: 22, SEQ ID NO: 18, SEQ ID NO: 14, SEQ ID NO: 24, SEQ ID NO: 20, and SEQ ID NO: 16;

(d) SEQ ID NO: 40;

(e) SEQ ID NO: 41;

(f) SEQ ID NO: 42;

(g) SEQ ID NO: 43; or

(h) SEQ ID NO: 44.

8. An isolated host cell comprising the isolated nucleic acid or nucleic acids of claim 7 .

9. An isolated cell line comprising the isolated nucleic acid or nucleic acids of claim 7 .

Assignments (4)
MERGER Recorded Jun 2, 2015
From: MEDAREX, L.L.C.
To: E. R. SQUIBB & SONS, L.L.C.
Reel/Frame 035767/0494 →
MERGER Recorded Aug 15, 2013
From: MEDAREX, INC.
To: MEDAREX, L.L.C.
Reel/Frame 031016/0678 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2010
From: WILD, KENNETH D, JR.; TREANOR, JAMES J.S.; HUANG, HAICHUN; INOUE, HEATHER
To: AMGEN INC
Reel/Frame 024739/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2010
From: AMGEN INC
To: MEDAREX, INC.
Reel/Frame 024739/0583 →